A cuproptosis-related lncRNA signature identified prognosis and tumour immune microenvironment in kidney renal clear cell carcinoma

Abstract

Kidney renal clear cell carcinoma (KIRC) is a heterogeneous malignant tumor with high incidence, metastasis, and mortality. The imbalance of copper homeostasis can produce cytotoxicity and cause cell damage. At the same time, copper can also induce tumor cell death and inhibit tumor transformation. The latest research found that this copper-induced cell death is different from the known cell death pathway, so it is defined as cuproptosis. We included 539 KIRC samples and 72 normal tissues from the Cancer Genome Atlas (TCGA) in our study. After identifying long non-coding RNAs (lncRNAs) significantly associated with cuproptosis, we clustered 526 KIRC samples based on the prognostic lncRNAs and obtained two different patterns (Cuproptosis.C1 and C2). C1 indicated an obviously worse prognostic outcome and possessed a higher immune score and immune cell infiltration level. Moreover, a prognosis signature (CRGscore) was constructed to effectively and accurately evaluate the overall survival (OS) of KIRC patients. There were significant differences in tumor immune microenvironment (TIME) and tumor mutation burden (TMB) between CRGscore-defined groups. CRGscore also has the potential to predict medicine efficacy.

Identification of a lactate metabolism-related lncRNAs signature for predicting the prognosis in patients with kidney renal clear cell carcinoma

“…Earlier research has demonstrated that the acidic pH in the TME also impacts the efficacy of immunotherapeutic agents ( 7 ). In the present study, significant differences were excited in the expression of immune checkpoints between the two risk groups, which were linked to the immunosuppressive microenvironment ( 35 ). We also observed that the risk score was positively correlated with the TMB.…”

Bioinformatics analysis and experimental validation of m6A and cuproptosis-related lncRNA NFE4 in clear cell renal cell carcinoma

“…Dihydrolipoamide Branched Chain Transacylase E2 (DBT), a key enzyme in transforming α-keto acid into acyl-CoA, served as a protective factor in cervical cancer [ 53 ]. FOXD2-AS1 and LINC02154 are the risk factors for KIRC patients [ 48 , 54 , 55 ]. Furthermore, some epigenetics regulators can modulate cuproptosis, including m6A.…”

A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments

“…For instance, researchers have identified and validated a lncRNA model of necroptosis that effectively predicts the survival of patients with glioma ( Wu et al, 2022 ). Numerous studies have been published highlighting the ability of cuproptosis-related lncRNAs (CRLs) to predict the survival of patients with breast cancer ( Jiang et al, 2022 ), hepatocellular carcinomas ( Zhu et al, 2022 ) and renal clear cell carcinomas ( Xin et al, 2022 ). However, to the best of our knowledge, there has been no systematic evaluation of whether CRLs can be utilized as biomarkers for the prognosis and treatment of glioma.…”